Pioglitazone increases bone marrow fat in type 2 diabetes: Results from a randomized controlled trial

European Journal of Endocrinology

Volumn 166, Issue 6, 2012, Pages 1087-1091

  Grey, Andrew ^a   Beckley, Vaughan ^a   Doyle, Anthony ^a   Fenwick, Sheryl ^a   Horne, Anne ^a   Gamble, Greg ^a   Bolland, Mark ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ADULT; ANATOMICAL VARIATION; ARTICLE; BODY FAT; BONE DENSITY; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HUMAN; LIPID ANALYSIS; LUMBAR SPINE; LUMBAR VERTEBRA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; AGED; BONE DENSITY; BONE MARROW; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HUMANS; HYPOGLYCEMIC AGENTS; LUMBAR VERTEBRAE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SPECTRUM ANALYSIS; THIAZOLIDINEDIONES;

EID: 84862748140     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-1075     Document Type: Article

References (19)

1. Yki-Jarvinen H. Thiazolidinediones. New England Journal of Medicine 2004 351 1106-1118. (doi:10.1056/NEJMra041001)
2. Pei L & Tontonoz P. Fat's loss is bone's gain. Journal of Clinical Investigation 2004 113 805-806. (doi:10.1172/JCI21311)
3. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporosis International 2008 19 129-137. (doi:10.1007/s00198-007-0477-y)
4. Grey AB. Thiazolidinedione-induced skeletal fragility - mechanisms and implications. Diabetes, Obesity and Metabolism 2009 11 275-284. (doi:10.1111/j.1463-1326.2008.00931.x)
5. Douglas IJ, Evans SJ, Pocock S & Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Medicine 2009 6 e1000154. (doi:10.1371/journal.pmed.1000154)
6. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J & Reid IR. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism 2007 92 1305-1310. (doi:10.1210/jc.2006-2646)
7. Gruntmanis U, Fordan S, Ghayee HK, Abdullah SM, See R, Ayers CR & McGuire DK. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcified Tissue International 2010 86 343-349. (doi:10.1007/s00223-010-9352-5)
8. Elbaz A, Wu X, Rivas D, Gimble JM & Duque G. Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. Journal of Cellular and Molecular Medicine 2010 14 982-991. (doi:10.1111/j.1582- 4934.2009.00751.x)
9. Devlin MJ, Cloutier AM, Thomas NA, Panus DA, Lotinun S, Pinz I, Baron R, Rosen CJ & Bouxsein ML. Caloric restriction leads to high marrowadiposityand lowbonemass ingrowingmice. Journal ofBone and Mineral Research 2010 25 2078-2088. (doi:10.1002/jbmr.82)
10. Rosen CJ & Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nature Clinical Practice Rheumatology 2006 2 35-43. (doi:10.1038/ncprheum0070)
11. Chappard D, Moquereau M, Mercier P, Gallois Y, Legrand E, Basle MF & Audran M. Ex vivo bone mineral density of the wrist: influence of medullar fat. Bone 2004 34 1023-1028. (doi:10.1016/j.bone.2004.02.002)
12. Harslof T, Wamberg L, Moller L, Stodkilde-Jorgensen H, Ringgaard S, Pedersen SB & Langdahl BL. Rosiglitazone decreases bone mass and bone marrowfat. Journal of Clinical Endocrinology and Metabolism 2011 96 1541-1548. (doi:10.1210/jc.2010-2077)
13. Schellinger D, Chin S, Fertikh D, Lee J, Lauerman W, Henderson F & Davis B. Normal lumbar vertebrae: anatomic, age and sex variance in subjects at proton MR spectroscopy initial experience. Radiology 2000 215 910-916. (Pubitemid 30346040)
14. Dixon WT. Simple proton spectroscopic imaging. Radiology 1984 153 189-194. (Pubitemid 14043406)
15. Baum T, Yap SP, Karampinos DC, Nardo L, Kuo D, Burghardt AJ, Masharani UB, Schwartz AV, Li X & Link TM. Does vertebral bonemarrowfat content correlatewith abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus? Journal of Magnetic Resonance Imaging 2012 35 117-124. (doi:10.1002/jmri.22757)
16. Loke YK, Singh S & Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ: Canadian Medical Association Journal 2009 180 32-39. (doi:10.1503/cmaj.080486)
17. Justesen J, Mosekilde L, Holmes M, Stenderup K, Gasser J, Mullins JJ, Seckl JR & Kassem M. Mice deficient in 11β-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation. Endocrinology 2004 145 1916-1925. (doi:10.1210/en.2003-1427)
18. Bilezikian JP, Eastell R, Nino AJ, Northcutt AR, Kravitz B, Paul G, Cobitz AR, Josse R & Fitzpatrick L. Rosiglitazone reduced BMD in women with type 2 diabetes and the effect was attenuated after switching to metformin. Journal of Bone and Mineral Research 2011 26 (Suppl 1).
19. Blake GM, Griffith JF, Yeung DKW, Leung PC & Fogelman I. Effect of increasing vertebral marrow fat content on BMD measurement, Tscore status and fracture risk prediction by DXA. Bone 2009 44 495-501. (doi:10.1016/j.bone.2008. 11.003)